Sensei Biotherapeutics Inc: Expects to Report Initial Data From Dose Expansion Cohorts and to Hold an End-of-Phase 1 Meeting With FDA by End of 2024
Sensei Biotherapeutics Inc:預計將報告劑量擴展隊列的初步數據,並將在2024年底之前與美國食品藥品管理局舉行第一階段結束會議
Sensei Biotherapeutics Inc: Expects to Report Initial Data From Dose Expansion Cohorts and to Hold an End-of-Phase 1 Meeting With FDA by End of 2024
Sensei Biotherapeutics Inc:預計將報告劑量擴展隊列的初步數據,並將在2024年底之前與美國食品藥品管理局舉行第一階段結束會議
譯文內容由第三人軟體翻譯。